{"disease":{"id":"prurigo","name":"prurigo"},"drugs":{"marketed":[{"drug_id":"dupilumab","indication_name":"Prurigo nodularis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dupixent","generic_name":"DUPILUMAB","company_name":"Regeneron","drug_phase":"marketed","molecular_target":"Interleukin-4 receptor subunit alpha","drug_class":"Interleukin-4 Receptor alpha Antagonist [EPC]","quality_score":62,"revenue":"14600","mechanism":"Dupixent blocks the interleukin-4 receptor, a key player in the immune system's inflammatory response."},{"drug_id":"chronic-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe prurigo nodularis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 450 mg SC Q4W","generic_name":"chronic-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-4 receptor alpha subunit","drug_class":"pharmacological class not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe prurigo nodularis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 450 mg SC Q4W","generic_name":"chronic-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-4 receptor alpha subunit","drug_class":"pharmacological class not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe prurigo nodularis in infants and children","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 450 mg SC Q4W","generic_name":"chronic-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-4 receptor alpha subunit","drug_class":"pharmacological class not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe prurigo nodularis in infants and children","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 450 mg SC Q4W","generic_name":"chronic-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-4 receptor alpha subunit","drug_class":"pharmacological class not specified","quality_score":40,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":5,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05316805","title":"China Type II Inflammatory Skin Disease Clinical Research and Standardized Diagnosis and Treatment Project","phase":"","overall_status":"RECRUITING","enrollment_count":100000,"lead_sponsor_name":"Peking University First Hospital","has_results":false},{"nct_id":"NCT05928169","title":"Determinants of Chronic Inflammatory Skin Disease Trajectories","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"University Hospital Schleswig-Holstein","has_results":false},{"nct_id":"NCT06988618","title":"Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Galderma R&D","has_results":false},{"nct_id":"NCT03540160","title":"Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":558,"lead_sponsor_name":"Vyne Therapeutics Inc.","has_results":true},{"nct_id":"NCT04204616","title":"A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Galderma R&D","has_results":false},{"nct_id":"NCT06527404","title":"A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":469,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT03497975","title":"PRISM Study-Pruritus Relief Through Itch Scratch Modulation","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":353,"lead_sponsor_name":"Trevi Therapeutics","has_results":true},{"nct_id":"NCT06516965","title":"A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":346,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT06516952","title":"A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":330,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT03677401","title":"Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":295,"lead_sponsor_name":"Vyne Therapeutics Inc.","has_results":true},{"nct_id":"NCT04501666","title":"Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":286,"lead_sponsor_name":"Galderma R&D","has_results":true},{"nct_id":"NCT03546816","title":"Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":285,"lead_sponsor_name":"Vyne Therapeutics Inc.","has_results":true},{"nct_id":"NCT04501679","title":"A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":274,"lead_sponsor_name":"Galderma R&D","has_results":true},{"nct_id":"NCT03816891","title":"Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":240,"lead_sponsor_name":"Genentech, Inc.","has_results":true},{"nct_id":"NCT06554509","title":"Clinical Study of the Efficacy and Safety of SHR-1819 Injection in Adult Patients With Prurigo Nodularis","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":236,"lead_sponsor_name":"Guangdong Hengrui Pharmaceutical Co., Ltd","has_results":false},{"nct_id":"NCT06342713","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":211,"lead_sponsor_name":"BeiGene","has_results":false},{"nct_id":"NCT05755438","title":"A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":204,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT06424470","title":"Study on the Treatment of Prurigo Nodularis With Stapokibart Injection","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Keymed Biosciences Co.Ltd","has_results":false},{"nct_id":"NCT05764161","title":"A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":190,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT06087627","title":"A Non-interventional Study to Describe the Dupilumab Long-term Treatment, Safety and Patient Reported Outcomes in Chronic Nodular Prurigo (Prurigo Nodularis) in Clinical Routine","phase":"","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT05061693","title":"A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":146,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT02196324","title":"A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":128,"lead_sponsor_name":"Vyne Therapeutics Inc.","has_results":true},{"nct_id":"NCT05991323","title":"Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT06427122","title":"Effect of EMD Protocol for Urge on Dermatology-specific Quality of Life","phase":"NA","overall_status":"COMPLETED","enrollment_count":96,"lead_sponsor_name":"Tamar Nijsten","has_results":false},{"nct_id":"NCT03181503","title":"Safety and Efficacy of Nemolizumab in PN","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"Galderma R&D","has_results":true},{"nct_id":"NCT06994520","title":"Efficacy of Topical Cannabidiol for Eczema","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Khon Kaen University","has_results":false},{"nct_id":"NCT06524323","title":"A Randomized, Double-blinded, Self-controlled Clinical Study of Intralesional Injection of 5-fluorouracil Plus Triamcinolone for the Treatment of Refractory Nodular Prurigo","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT07055009","title":"Multi-centred Clinico-genetic Study of Actinic Prurigo in Thailand","phase":"","overall_status":"RECRUITING","enrollment_count":47,"lead_sponsor_name":"Chulalongkorn University","has_results":false},{"nct_id":"NCT07276425","title":"Early and Long-Term Efficacy and Immune Changes With Dupilumab in Prurigo Nodularis","phase":"","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"UMC Utrecht","has_results":false},{"nct_id":"NCT02174432","title":"Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"Trevi Therapeutics","has_results":true},{"nct_id":"NCT05052983","title":"A Study to Evaluate the Durability of Response and Safety of Nemolizumab for 24 Weeks in Participants With Prurigo Nodularis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"Galderma R&D","has_results":true},{"nct_id":"NCT03630198","title":"Pain Outcomes Following Intralesional Corticosteroid Injections","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":31,"lead_sponsor_name":"Vanderbilt University Medical Center","has_results":true},{"nct_id":"NCT04944862","title":"A Study of CDX-0159 in Patients With Prurigo Nodularis","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Celldex Therapeutics","has_results":false},{"nct_id":"NCT06201715","title":"Efficacy and Safety of Tofacitinib in Patients With Prurigo Nodularis","phase":"NA","overall_status":"UNKNOWN","enrollment_count":24,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT06213831","title":"A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":23,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT05038982","title":"Efficacy of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown Origin","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Johns Hopkins University","has_results":true},{"nct_id":"NCT06293053","title":"A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT03576287","title":"Apremilast as Anti-pruritic Treatment in Patients With Prurigo Nodularis","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":15,"lead_sponsor_name":"Tanja Todberg, MD","has_results":false}],"total":38},"guidelines":[],"source":"Drug Landscape verified database"}